Weight loss drug works less well for emotional eaters, better for foodies

A recent study originating from Japan offers a nuanced perspective on the efficacy of GLP-1 obesity medications, suggesting their effectiveness varies significantly based on an individual's eating triggers. Published in Frontiers in Clinical Diabetes and Healthcare, the research indicates that these drugs, commonly used for type 2 diabetes and weight management, work best for individuals whose appetite is stimulated by external cues, such as the sight or smell of appealing food. These participants experienced the most substantial reductions in appetite, weight loss, and improvements in blood sugar levels.

Conversely, the study found that GLP-1 medications were considerably less effective for 'emotional eaters' – those who consume food in response to internal states like stress, sadness, or anxiety. While these individuals initially showed some reduction in eating habits within the first three months, their eating patterns returned to baseline levels by the end of the year-long study. This suggests that the psychological underpinnings of emotional eating may be a barrier that current GLP-1 therapies cannot directly overcome.

Takehiro Kato, a co-author of the study, posited that the psychological factors influencing emotional eating are complex and may require different therapeutic approaches. The research tracked 92 participants with type 2 diabetes who were prescribed GLP-1 medications like semaglutide or dulaglutide. Participants were categorized based on their eating behaviors: emotional eating, restrictive eating, and cue-induced eating. The findings underscore that while GLP-1 drugs are a powerful tool for many, they are not a one-size-fits-all solution, particularly for those whose eating is deeply intertwined with their emotional well-being.

From a Finnish perspective, where public health discussions often emphasize holistic approaches to weight management, this study highlights the importance of understanding individual eating psychology. While the development of effective pharmacological treatments like GLP-1 agonists is celebrated, it's crucial to recognize their limitations. Helsingin Sanomat would emphasize that these findings do not diminish the value of the drugs but rather call for integrated treatment plans. This might include psychological support or behavioral therapy alongside medication, especially for individuals struggling with emotional eating. The study reinforces the idea that successful weight management often requires addressing both physiological and psychological dimensions of eating behavior.

“

It may be that psychological factors influence emotional eating more, which GLP-1 treatment cannot directly affect.